Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.58 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.58 |
| ▸ | XDH | P47989 | 3/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | BLVRB | P30043 | 1/20 | 0.53 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30804867 | 1.00 | CDC7 (0.58) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL19523342 | 0.87 | XDH (0.65) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL19523349 | 0.87 | XDH (0.60) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL28504761 | 0.85 | XDH (0.57) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL25083600 | 0.84 | XDH (0.56) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL12186978 | 0.84 | CDC7 (0.64) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL438271 | 0.84 | XDH (0.68) | XDHABCC4ABCB11PGRCHRM1 | |
| SCHEMBL28488461 | 0.84 | XDH (0.44) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL20195691 | 0.84 | CDC7 (0.55) | CDC7DBF4XDHABCC4ABCB11 | |
| SCHEMBL8868180 | 0.84 | XDH (0.77) | CDC7DBF4XDHABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772137-B | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117777050-A | Febuxostat 4-position ether derivative and pharmaceutical composition, preparation method and application thereof | 广西师范大学 | 2024-03-29 | — | — | CN | claimed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| WO-2014057461-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM G OF FEBUXOSTAT | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-17 | — | — | WO | claimed |
| CN-119350357-A | Phenyl ether compound containing hexahydrofuro [3,2-b ] furan structure and application thereof | 沈阳药科大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-115772137-B | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117777050-A | Febuxostat 4-position ether derivative and pharmaceutical composition, preparation method and application thereof | 广西师范大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-109444304-B | HPLC (high performance liquid chromatography) detection method for febuxostat and related impurities thereof | 湖南新领航检测技术有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-109320474-B | Preparation method of febuxostat | 昆明源瑞制药有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2011031409-A1 | PROCESSES FOR PREPARING FEBUXOSTAT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | CDC7 4460/4885DBF4 1750/4885XDH 1/4885 |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | XDH, NLRP3, UACA | CDC7 4717/4885DBF4 2805/4885XDH 1/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | CDC7 4460/4885DBF4 1750/4885XDH 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.